NasdaqGM - Delayed Quote • USD
Skye Bioscience, Inc. (SKYE)
At close: 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -0.16 | -0.14 | -0.78 | -0.87 |
| Low Estimate | -0.16 | -0.14 | -0.92 | -0.92 |
| High Estimate | -0.16 | -0.14 | -0.65 | -0.83 |
| Year Ago EPS | -- | -- | -5.37 | -0.78 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2023 | |||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -0.38 |
| EPS Actual | -- | -- | -- | -0.63 |
| Difference | -- | -- | -- | -0.25 |
| Surprise % | -- | -- | -- | -65.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.14 | -0.78 | -0.87 |
| 7 Days Ago | -0.16 | -0.14 | -0.78 | -0.87 |
| 30 Days Ago | -0.16 | -0.14 | -0.65 | -0.92 |
| 60 Days Ago | -0.15 | -0.15 | -0.64 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SKYE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 6.50% |
| Next Qtr. | -- | -- | -- | 12.00% |
| Current Year | 85.50% | -- | -- | 5.30% |
| Next Year | -11.50% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Oppenheimer: Outperform | 4/12/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 3/14/2024 |
| Initiated | Piper Sandler: Overweight | 2/5/2024 |
Related Tickers
SLNO Soleno Therapeutics, Inc.
37.89
+1.47%
JANX Janux Therapeutics, Inc.
47.39
+0.62%
KRRO Korro Bio, Inc.
62.93
+7.52%
MLTX MoonLake Immunotherapeutics
42.49
+0.57%
BOLD Boundless Bio, Inc.
11.64
-3.56%
ELEV Elevation Oncology, Inc.
3.6200
-0.69%
KURA Kura Oncology, Inc.
19.65
+3.42%
VIGL Vigil Neuroscience, Inc.
2.7100
+5.04%
ZURA Zura Bio Limited
4.4100
+21.82%
ADXN Addex Therapeutics Ltd
16.10
+4.48%